Marine Gilabert

Marine Gilabert

Auto-generated profile, based on publicly available information

Marine Gilabert

Department of Oncology, Institut Paoli-Calmettes, Marseille, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Philippe RochigneuxPhilippe Rochigneux
Philippe Rochigneux
BCBrice Chanez
Brice Chanez
BRBernadette De Rauglaudre
Bernadette De Rauglaudre
EMEmmanuel Mitry
Emmanuel Mitry
CCChristian Chabannon
Christian Chabannon
MGMarine Gilabert
Marine Gilabert
The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. In unresectable HCC, the cornerstone of systemic treatments is switching from tyrosine kinase inhibitors to immune checkpoints inhibitors (ICI). Next to ICI, adoptive cell transfer represents another promising field of immunotherapy. Targeting tumor associated antigens such as alpha-fetoprotein (AFP), glypican-3 (GPC3), or New York esophageal squamous cell carcinoma-1 (NY-ESO-1), T cell receptor (TCR) engineered T cells and chimeric antigen receptors (CAR) engineered T cells are emerging as potentially effective therapies, with objective responses reported in early phase trials. In this review, we address the biological rationale of TCR/CAR engineered T cells in advanced HCC, their mechanisms of action, and results from recent clinical trials.

25 July 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
Alexia Melanie LOPRESTIAlexia Melanie LOPRESTI
Alexia Melanie LOPRESTI
FMFabrice Malergue
Fabrice Malergue
FBFrançois Bertucci
François Bertucci
MLMARIA LUCIA LIBERATOSCIOLI
MARIA LUCIA LIBERATOSCIOLI
SGSeverine Garnier
Severine Garnier
Emilie MamessierEmilie Mamessier
Emilie Mamessier
Circulating tumor cells (CTCs) provide easy, repeatable, and representative access to information regarding solid tumors. However, their detection remains difficult because of their paucity, their short half-life, and the lack of reliable surface biomarkers. Flow cytometry (FC) is a fast, sensitive, and affordable technique, ideal for rare-cell detection. Adapted to CTC detection (i.e., extremely rare cells), most FC-based techniques require a time-consuming pre-enrichment step, followed by a 2-hour staining procedure, impeding the efficiency of CTC detection. We overcame these caveats and reduced the procedure to less than 1 hour, with minimal manipulation. First, cells were simultaneously fixed, permeabilized, and then stained. Second, using low-speed FC acquisition conditions and 2 discriminators (cell size and pan-cytokeratin expression), we suppressed the pre-enrichment step. Applied to blood from donors with or without known malignant diseases, this protocol ensures a high recovery of the cells of interest independently of their epithelial-mesenchymal plasticity and can predict which samples are derived from cancer donors. This proof-of-concept study lays the bases of a sensitive tool to detect CTCs from a small amount of blood upstream of in-depth analyses.

19 April 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MFMarjorie Faure
Marjorie Faure
Philippe RochigneuxPhilippe Rochigneux
Philippe Rochigneux
DODaniel Olive
Daniel Olive
STSébastien Taix
Sébastien Taix
IBIsabelle Brenot-Rossi
Isabelle Brenot-Rossi
MGMarine Gilabert
Marine Gilabert
The 5-year survival rate of primary anorectal malignant melanoma is less than 20%. Optimal treatment of this condition remains controversial regarding locally disease, and whether any preferential survival benefit arises from either abdominoperineal resection or wide local excision remains unknown. The majority of patients progress to metastatic disease, and for decades, the use of chemotherapies, such as platines or dacarbazine, has been advocated to improve overall survival. The therapeutic use of new checkpoint inhibitors in a variety of trials has provided evidence for an antitumoral effect of PD-1 and/or CTL4 inhibitors in mucosal melanomas, but these treatments must still be further evaluated. Some anecdotal occurrences of rapid progression [i.e., hyperprogressive disease (HPD)] while using these immune agents have been described, suggesting potentially deleterious effects of these drugs for some patients. We report a 77-year-old male metastatic anorectal melanoma patient presenting with HPD over 2 months of a PD1 inhibitor treatment course and document this HPD blood phenotype.

1 April 2017 in Medicine
Verified
Journal Article
Open access
PDF file
MGMarine Gilabert
Marine Gilabert
BCBrice Chanez
Brice Chanez
YRYoung Soo Rho
Young Soo Rho
MGMarc Giovanini
Marc Giovanini
OTOlivier Turrini
Olivier Turrini
JRJean-Luc Raoul
Jean-Luc Raoul
To evaluate gemcitabine efficacy in advanced pancreatic cancer patients after the FOLFIRINOX regimen. Patients with locally-advanced or metastatic pancreatic adenocarcinoma from French and Canadian centers, who were treated with the first-line FOLFIRINOX regimen (FFX L1), followed by gemcitabine monotherapy as a second-line treatment (GEM L2), were retrospectively evaluated. Statistical analyses were performed on the demographic, toxicity, and response rate data. Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan–Meier method. Seventy-two patients were reviewed (median age of 63.5 years [range, 32–75 years], men [62%], predominantly pancreatic head tumor location [51%] and metastatic disease [64%] at the time of diagnosis). The objective response rate to GEM-L2 treatment was 8/72 (11%), and 32 patients (44%) experienced a clinical benefit from gemcitabine. Four patients had a partial response to GEM-L2, although they previously showed a progressive response following FFX-L1 treatment. The median OS for the entire cohort was 13.6 months (95% confidence interval [CI]: 2.0–35). The median PFS of the GEM-L2 group was 2.5 months (95% CI: 0.2–10.8) with no statistical differences between patients with controlled or progressive disease on FFX-L1 therapy. Gemcitabine as a second-line treatment for advanced pancreatic adenocarcinoma after FOLFIRINOX failure showed clinical benefits in some patients.

1 October 2019 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
AFAbdallah Yahya Al Farai
Abdallah Yahya Al Farai
JGJonathan Garnier
Jonathan Garnier
JEJacques Ewald
Jacques Ewald
UMUgo Marchese
Ugo Marchese
MGMarine Gilabert
Marine Gilabert
OTOlivier Turrini
Olivier Turrini

24 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JRJean-Luc Raoul
Jean-Luc Raoul
JEJulien Edeline
Julien Edeline
VSVictor Simmet
Victor Simmet
Camille Moreau-BachelardCamille Moreau-Bachelard
Camille Moreau-Bachelard
MGMarine Gilabert
Marine Gilabert
JFJean-Sebastien FRENEL
Jean-Sebastien FRENEL
Multikinase inhibitors (MKIs), and particularly tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (CPIs), are currently some of the major breakthroughs in cancer treatment. Proton pump inhibitors (PPIs) revolutionised the treatment of acid-related diseases, but are frequently overused for epigastric pain or heartburn. However, long-term acid suppression from using PPIs may lead to safety concerns, and could have a greater impact in cancer patients undergoing therapy, like bone fractures, renal toxicities, enteric infections, and micronutrient deficiencies (iron and magnesium). Moreover, acid suppression may also affect the pharmacokinetics of drugs (at least during acid suppression) and decrease the absorption of many molecularly-targeted anticancer therapies, which are mostly weak bases with pH-dependent absorption. This type of drug-drug interaction may have detrimental effects on efficacy, with major clinical impacts described for some orally administrated targeted therapies (erlotinib, gefitinib, pazopanib, palbociclib), and conflicting results with many others, including capecitabine. Furthermore, the long-term use of PPIs results in severe alterations to the gut microbiome and recent retrospective analyses have shown that the benefit of using CPIs was suppressed in patients treated with PPIs. These very expensive drugs are of great importance because of their efficacy. As the use of PPIs is not essential, we must apply the precautionary principle. All these data should encourage medical oncologists to refrain from prescribing PPIs, explaining to patients the risks of interaction in order to prevent inappropriate prescription by another physician.